How do you spell relief for irritable bowel syndrome?

Journal of Family Practice

Volumn 57, Issue 2, 2008, Pages 100-108

  Moynihan, Neil T ^a,b   Callahan, Michael J ^c   Kalsmith, Benjamin ^d   Moses, Peter L ^e  

^a Johnson Memorial Hospital   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BENZODIAZEPINE; CHLORIDE CHANNEL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DICYCLOVERINE; FLUOXETINE; HYOSCYAMINE; ISPAGULA; LACTULOSE; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MEBEVERINE; OTILONIUM BROMIDE; PAROXETINE; PEPPERMINT OIL; PINAVERIUM BROMIDE; POLYCARBOPHIL; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ACUPUNCTURE; ADULT; BACTERIAL OVERGROWTH; BEHAVIOR THERAPY; CASE REPORT; CHINESE MEDICINE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DIAGNOSTIC TEST; DIET THERAPY; DRUG EFFICACY; FAMILY HISTORY; FEMALE; GASTROENTERITIS; GENETIC RISK; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LOW DRUG DOSE; MENTAL STRESS; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SYMPTOM; TEA;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMBINED MODALITY THERAPY; CONSTIPATION; DIARRHEA; DIETARY FIBER; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; LAXATIVES; MALE; PAIN THRESHOLD; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 39449095407     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130:1480-1491.
2. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569-1580.
3. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986; 27:37-40.
4. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20(suppl):3-14.
5. Mawe GM, Coates M, Moses PL. Review article: intestinal serotonin signaling in irritable bowel syndrome. Alimentary Pharmacol Ther 2006; 23:1067-1076.
6. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005; 17:637-642.
7. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005; 39(suppl):184-193.
8. Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17:5-9.
9. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44:400-406.
10. Wang L-H, Fang X-C, Pan G-Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-1101.
11. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98:1578-1583.
12. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
13. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18:77-84.
14. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-3506.
15. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double blind, randomized controlled study. Am J Gastroenterol 2003; 98:412-419.
16. Posserud I, Stotzer ES, Bjornsson H, Abrahamsson M, Simren M. Altered counts of small bowel bacteria in patients with irritable bowel syndrome (IBS). Gastroenterology 2006; 130:A739.
17. Ruff KC, Saito-Loftus YA, Locke GR, Harmsen WS, Zinsmeister AS, Talley NJ. Failure to detect association with irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). Am J Gastroenterol 2006; 101(suppl 2):S488.
18. Bellentani S, Baldoni P, Petrella S, et al. A simple score for the identification of patients at high risk of organic diseases of the colon in the family doctor consulting room: the Local IBS Study Group. Fam Pract 1990; 7:307-312.
19. Saito YA, Petersen GM, Locke R III, Talley NJ. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:1057-1065.
20. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990; 113:828-833.
21. Drossman DA, Li Z, Leserman J, Toomey TC, Hu Y. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996; 110:999-1007.
22. Malagelada JR. A symptom based approach to making a positive diagnosis of irritable bowel syndrome with constipation. Int J Clin Pract 2006; 60:57-63.
23. Locke GR 3rd. Natural history of irritable bowel syndrome and durability of diagnosis. Rev Gastroenterol Disord 2003; 3(suppl):S12-S17.
24. Cole JA, Yeaw JM, Cutone JA, et al. The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome. Dig Dis Sci 2005; 50:2268-2275.
25. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol Clin N Am 2005; 34:205-220.
26. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122:107-112.
27. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1-4.
28. Spiegel BM, Derosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effective analysis. Gastroenterology 2004; 126:1721-1732.
29. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97(suppl 11):S1-S5.
30. Cremonini F, Delgado A and Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79-86.
31. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; (1):CD003960.
32. US Food and Drug Administration. FDA Public Health Advisory: Tegaserod maleate (marketed as Zelnorm). March 30, 2007. Available at: www.fda.gov/CDER/Drug/advisory/tegaserod.htm. Accessed January 2, 2008.
33. US Food and Drug Administration. FDA Permits restricted use of Zelnorm for qualifying patients. July 27, 2007. Available at: www.fda.gov/bbs/topics/ NEWS/2007/NEW01673.html. Accessed January 2, 2008.
34. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25:1271-1281.
35. Quartern AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; (2):CD003460.
36. Jailwala J, Impereiale T, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials. Ann Intern Med 2000; 133:136-147.
37. Johanson JF, Panas R, Holland P, Ueno R. A dose ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS). Gastroenterology 2006; 130(suppl 2):A25.
38. Amery W, Duyck F, Polak J, van den Bouwhuysen G. A multicentre double-blind study in acute diarrhoea comparing loperamide (R 18553) with two common antidiarrhoeal agents and a placebo. Curr Ther Res Clin Exp 1975; 17:263-270.
39. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24:183-205.
40. Bleser SD. Chronic constipation: Let symptom and severity direct treatment. J Fam Pract 2006; 55:587-593.
41. Wald A. Psychotropic agents in irritable bowel syndrome. J Clin Gastroenterol 2002; 35(suppl):S53-S57.
42. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers A, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55:1095-1103.
43. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004 May; 99:914-920.
44. Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (4):CD005111.
45. Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (1):CD004116.
46. Quigley EMM, Flourie B. Probiotics and irritable bowel syndrome: a rational for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007; 19:166-172.
47. Wilson S, Maddison T, Robers L, Greenfield S, Singh S, on behalf of the Birmingham IBS research group. Systematic review: The effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24:769-780.
48. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004; 72:1100-1113.
49. Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004; 99:486-491.
50. Grigoleit HG, Grigoleit P. Peppermint oil in irritable bowel syndrome. Phytomedicine 2005; 12:601-606.